Kyowa Kirin CoKYKOF 82 Return-on-Tangible-Equity is 26.82% as of Dec. 2025, which is 150% above its 10-year median of 10.72. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.92 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 898 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 69.38% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Kyowa Kirin Co's annualized net income for the quarter that ended in Dec. 2025 was $884 Mil. Kyowa Kirin Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $3,294 Mil. Therefore, Kyowa Kirin Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 26.82%.
The historical rank and industry rank for Kyowa Kirin Co's Return-on-Tangible-Equity or its related term are showing as below:
KYKOF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.87 Med: 10.72 Max: 14.54
Current: 14.54
During the past 13 years, Kyowa Kirin Co's highest Return-on-Tangible-Equity was 14.54%. The lowest was 7.87%. And the median was 10.72%.
KYKOF's Return-on-Tangible-Equity is ranked better than 69.38% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs KYKOF: 14.54
Kyowa Kirin Co (OTCPK:KYKOF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Kyowa Kirin Co Return-on-Tangible-Equity Related Terms
Kyowa Kirin Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KYKOF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 26.82% mean?
Kyowa Kirin Co (KYKOF) has a Return-on-Tangible-Equity of 26.82% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kyowa Kirin Co and its competitors. This is 150% above median its historical median of 10.72. Over the past decade, Kyowa Kirin Co's Return-on-Tangible-Equity has ranged from 7.87 to 14.54. According to the industry distribution chart, Kyowa Kirin Co ranks #275 out of 898 companies in the Drug Manufacturers industry, placing it in the top 30.6%.
Is Kyowa Kirin Co's Return-on-Tangible-Equity too high?
Kyowa Kirin Co's current Return-on-Tangible-Equity of 26.82% is 150% above median its 10-year median of 10.72. Over the past 10 years, this metric has ranged from a low of 7.87 to a high of 14.54. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Kyowa Kirin Co's value of 26.82% is 240.4% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #275 out of 898 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #275 out of 898 companies for Return-on-Tangible-Equity. This puts Kyowa Kirin Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.88. Kyowa Kirin Co's value of 26.82% is 240.4% above this benchmark. Historically, Kyowa Kirin Co's own Return-on-Tangible-Equity has ranged from 7.87 to 14.54 over the past decade. While the company's 10-year median is 10.72 vs. the industry median of 7.88, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Return-on-Tangible-Equity of 26.82% is 240.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Return-on-Tangible-Equity is 26.82%, which is 150% above median its own 10-year median of 10.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.92, compared to a current price of $14.43 — trading 19.5% below its estimated fair value. The current Return-on-Tangible-Equity is 26.82%, which is 150% above median its 10-year median of 10.72 and 240.4% above the Drug Manufacturers industry median of 7.88. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Return-on-Tangible-Equity is 26.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 19.5% below its estimated GF Value™ of $17.92.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
Return-on-Tangible-Equity: 26.82% (150% above median its 10-year median of 10.72)
GF Value™: $17.92 vs. price of $14.43 (19.5% below fair value)
Industry Position: 240.4% above the Drug Manufacturers median (#275 of 898)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
